MARKET

AVXL

AVXL

Anavex Life Scie
NASDAQ
5.92
+0.09
+1.54%
After Hours: 5.98 +0.06 +1.01% 18:34 07/17 EDT
OPEN
5.70
PREV CLOSE
5.83
HIGH
5.98
LOW
5.58
VOLUME
923.07K
TURNOVER
0
52 WEEK HIGH
10.45
52 WEEK LOW
3.250
MARKET CAP
501.08M
P/E (TTM)
-11.9331
1D
5D
1M
3M
1Y
5Y
1D
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Anavex Life Sciences (NASDAQ:AVXL) has a high rate of cash burn. The company's cash burn is the annual rate at which it spends cash to fund its growth. Anavex had a cash runway of 4.3 years as at March 2024. Its cash burn rate has increased by 28% in the last year. While the company has a solid cash runway, its cash burn trajectory may have shareholders concerned. The firm has 3 warning signs we think you should know about.
Simply Wall St · 21h ago
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Shares of CrossFirst Bankshares, Inc. Fell sharply in today's pre-market trading following second-quarter results. The Nasdaq futures gained around 40 points on Tuesday. U.S. Stock futures were mixed this morning, with the Nasdaq up 40 points.
Benzinga · 1d ago
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Match Group, Inc. Shares jumped 8% in today's pre-market trading. The online dating company's shares jumped around 6.5% on Monday. Starboard Value has taken a keen interest in Match Group and is advocating for a sale. Conduit Pharmaceuticals Inc. And Trump Media & Technology Group Corp. Were among the stocks moving in pre- market trading.
Benzinga · 2d ago
Weekly Report: what happened at AVXL last week (0708-0712)?
Weekly Report · 3d ago
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
NASDAQ · 07/09 14:37
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
NASDAQ · 07/09 14:19
Weekly Report: what happened at AVXL last week (0701-0705)?
Weekly Report · 07/08 09:09
Weekly Report: what happened at AVXL last week (0624-0628)?
Weekly Report · 07/01 09:09
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Webull offers Anavex Life Sciences Corp stock information, including NASDAQ: AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.